Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Risk of TB Higher for Patients Taking Infliximab, Adalimumab, Than Etanercept - (DGNews)
    Golimumab Effective in Patients With RA Who Have Poor Response to Other Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/25/2009 - (DGNews)
    Initial Therapy With Adalimumab Plus Methotrexate Leads to Better Outcomes Over 5 Years in Patients With Early Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept Plus Methotrexate Safe, Effective for Up to 5 Years in Patients With Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis
    • Safety of Novel Immunomodulatory Therapies
      Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      New Recommendations for Disease-Modifying Antirheumatic Drugs and Emerging Options for the Treatment of Rheumatoid Arthritis
      Failing a TNF Inhibitor: What About Switching?

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Autologous Chondrocyte Implantation for Rheumatoid Arthritis of the Knee: A Case Report
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report
        Aseptic Meningitis in a Patient Taking Etanercept for Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Cytokine Key In Clinical Activity In Rheumatoid Arthritis

        A DGReview of :"Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations"
        Rheumatology Online

        05/30/2002
        By Anne MacLennan


        Synovial expression of macrophage migration inhibitory factor is strongly correlated with clinical disease activity in patients with rheumatoid arthritis.

        This finding from a joint study in Australia and the United States adds significant weight to evidence for the importance of this cytokine's role in rheumatoid arthritis (RA).

        In fact, migration inhibitory factor is an important member of the cytokine hierarchy in this disease, suggest these researchers from Monash Medical Centre, Melbourne, Repatriation General Hospital, Adelaide, and Picower Institute for Medical Research, Manhasset, New York.

        Cytokines are known to be key in the pathology of RA, and MIF is one with a broad spectrum of actions. These include induction of monocyte tumour necrosis factor a (TNF-a).

        MIF expression and proinflammatory activity in RA synovium and in animal models of the disease has been demonstrated recently. However, E. F. Morand and colleagues sought to assess the link between synovial MIF and clinical disease.

        Using paired sample from eight patients with active and inactive/treated disease, the researchers compared computer-assisted analysis of cytokine content of arthroscopically obtained biopsies of RA synovium with documented clinical parameters.

        Synovial MIF immunostaining correlated strongly with disease activity as measured by CRP concentration.

        Moreover, significant reductions in synovial MIF were found to accompany reductions in clinical disease parameters, including CRP, and tender and swollen joint counts.

        Synovial TNF-a, transforming growth factor b (TGF-b) and interleukin (IL)10 also showed a significant reduction in association with reduced disease activity; IL-1b and IL-1 receptor agonist did not.

        The demonstration that only MIF and TNF-a show significant variation in synovial cytokine content with clinical remission points to MIF' s importance in the cytokine hierarchy in RA, these authors conclude.
        Rheumatology 2002; 41: 558-562. "Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send